Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib

@article{Takemoto2008ClinicalPA,
  title={Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib},
  author={J. K. Takemoto and Jonathan K. Reynolds and C. Remsberg and K. R. Vega-Villa and N. M. Davies},
  journal={Clinical Pharmacokinetics},
  year={2008},
  volume={47},
  pages={703-720}
}
  • J. K. Takemoto, Jonathan K. Reynolds, +2 authors N. M. Davies
  • Published 2008
  • Medicine
  • Clinical Pharmacokinetics
  • The NSAID etoricoxib is a selective inhibitor of cyclo-oxygenase 2 (COX-2), approved for treatment of patients with chronic arthropathies and musculoskeletal and dental pain. The rate of absorption of etoricoxib is moderate when given orally (the maximum plasma drug concentration occurs after ∼1 hour), and the extent of absorption is similar with oral and intravenous doses. Etoricoxib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 120 L… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 81 REFERENCES
    Pharmacokinetics of Rofecoxib
    • 23